ReviewEmerging infectious diseases2022
Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019.
Review in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Epidemiology and outcomes of invasive fungal infections in patients with mature T-cell and NK-cell lymphomas.Annals of medicine · 2026Article
- Changes in age composition and epidemiology of candidaemia, Iceland, 2012 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Non-English Preferred Language and Hospital Mortality in Candidemia: A Retrospective Cohort Study.Open forum infectious diseases · 2026Article
- Evaluating the impact of immunization with the "pan-fungal" vaccine, NXT-2, on the gut mycobiome and microbiome in non-human primates (NHPs).Microbiology spectrum · 2026Article
- Demographics and Geographic Accessibility of Invasive Fungal Infection Clinical Trial Sites.JAMA network open · 2026Article
- Superficial Fungal Infection Associations with Comorbid Diseases and Risk Factors: An Analysis of Global Burden of Disease 2023.Infectious disease reports · 2026Article
- The problem with one-size-fits-all medicine: Biological sex and the aging immune system.PLoS biology · 2026Article
- Epidemiology of Aspergillosis Diagnoses in US Adults Using a National EHR Database, 2013-2023.Open forum infectious diseases · 2026Article
- Yeast infections in sterile body fluids: species distribution, antifungal susceptibility, and cross-cutting risk factors for fungemia, sepsis, and mortality (2019-2023).Frontiers in microbiology · 2026Article
- Azole Antifungals Under Pressure: Therapeutic Challenges and Multifaceted Resistance Mechanisms.Current medicinal chemistry · 2026Review
- Risk Factors Associated With Major Skin Diseases: A Cross-Sectional Study From Bangladesh.Global health, epidemiology and genomics · 2026Article
- Active and Passive Immunization of Pan-Fungal Vaccine NXT-2 Reduces Morbidity and Mortality in an Immunosuppressed Murine Model ofVaccines · 2025Article
- Epidemiology of and Risk Factors Associated with Mortality from Invasive Pulmonary Fungal Infection in Non-Neutropenic Patients in China: A 10-Year Retrospective Study.The American journal of tropical medicine and hygiene · 2025Article
- Chromoblastomycosis and phaeohyphomycotic abscess-associated hospitalizations, United States, 2016-2021.PLoS neglected tropical diseases · 2025Article
- Emerging Infections Network Survey of Screening for Cryptococcal Antigenemia, United States, 2024.Emerging infectious diseases · 2025Article
- Comparison of Patients With Coccidioidomycosis in Arizona Versus California: A Commercial Health Insurance Claims Analysis.Open forum infectious diseases · 2025Article
- Antifungal Resistance Among Candida Species: Diagnostic and Clinical Challenges in Specialized Cancer Care Hospital of Lahore.Journal of clinical laboratory analysis · 2025Article
- Past, present and future of antifungals: Advancements in mechanisms of action and resistance.Current research in microbial sciences · 2025Article
- Cryptococcal pericarditis with unexplained lymphadenopathy in an immunocompetent patient: a case report.Frontiers in medicine · 2025Article
- Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016-2022.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.